Matrix Metalloproteinases as Biomarkers of Atherosclerotic Plaque Instability.
Wioletta OlejarzDominika ŁachetaGrażyna Kubiak-TomaszewskaPublished in: International journal of molecular sciences (2020)
Matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases responsible for tissue remodeling and degradation of extracellular matrix (ECM) proteins. MMPs may modulate various cellular and signaling pathways in atherosclerosis responsible for progression and rupture of atherosclerotic plaques. The effect of MMPs polymorphisms and the expression of MMPs in both the atherosclerotic plaque and plasma was shown. They are independent predictors of atherosclerotic plaque instability in stable coronary heart disease (CHD) patients. Increased levels of MMPs in patients with advanced cardiovascular disease (CAD) and acute coronary syndrome (ACS) was associated with future risk of cardiovascular events. These data confirm that MMPs may be biomarkers in plaque instability as they target in potential drug therapies for atherosclerosis. They provide important prognostic information, independent of traditional risk factors, and may turn out to be useful in improving risk stratification.
Keyphrases
- coronary artery disease
- cardiovascular events
- cardiovascular disease
- extracellular matrix
- acute coronary syndrome
- risk factors
- percutaneous coronary intervention
- end stage renal disease
- ejection fraction
- signaling pathway
- newly diagnosed
- poor prognosis
- type diabetes
- chronic kidney disease
- emergency department
- electronic health record
- prognostic factors
- climate change
- social media
- sensitive detection
- quantum dots
- atrial fibrillation
- pi k akt
- endoplasmic reticulum stress
- drug induced
- deep learning
- living cells